<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study was to investigate the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppression efficacy of a <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitor, <z:chebi fb="0" ids="9925">sodium valproate</z:chebi> combined with adriamycin in the treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> cell line MUTZ-1 </plain></SENT>
<SENT sid="1" pm="."><plain>After treated with different concentrations of <z:chebi fb="0" ids="9925">sodium valproate</z:chebi> alone, adriamycin alone or combination of them, growth curve of MUTZ-1 cell line were detected; growth of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells were analyzed by flow cytometry and <z:mp ids='MP_0000002'>morphology</z:mp> method </plain></SENT>
<SENT sid="2" pm="."><plain>The results indicated that when the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> cell line MUTZ-1 was treated with adriamycin (0.039 microg/ml, 0.078 microg/ml, 0.156 microg/ml, 0.312 microg/ml, 0.4 microg/ml), the <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> inhibition rates were 5.08 +/- 0.79%, 12.32 +/- 2.39%, 23.65 +/- 1.34%, 43.33 +/- 2.38% and 47.85 +/- 1.46% (p &lt; 0.05), 0.25 mmol/L <z:chebi fb="0" ids="9925">sodium valproate</z:chebi> did not show <z:mpath ids='MPATH_3'>apoptosis</z:mpath> effect, but could synergize adriamycin to promote <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>When the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> cell line MUTZ-1 treated with two drug combination, the <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> inhibition rates were 23.46 +/- 1.12%, 49.87 +/- 0.84%, 52.37 +/- 1.05%, 78.43 +/- 4.34% and 82.47 +/- 1.04% (p &lt; 0.05), and displayed concentration-dependent manner </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> the data above were significantly different from those in control (p &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="9925">Sodium valproate</z:chebi> showed obvious effect at concentration of 0.078 microg/ml adriamycin </plain></SENT>
<SENT sid="6" pm="."><plain>After treated with 0.25 mmol/L <z:chebi fb="0" ids="9925">sodium valproate</z:chebi> and 0.078 microg/ml adriamycin for 72 hours, MUTZ-1 cell line showed typical <z:mpath ids='MPATH_3'>apoptosis</z:mpath> morphological character </plain></SENT>
<SENT sid="7" pm="."><plain>It is concluded that <z:chebi fb="0" ids="9925">sodium valproate</z:chebi> may enhance the efficacy of adriamycin on MUTZ-1 cell line </plain></SENT>
</text></document>